---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-23-000103"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T15:29:23.685083+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Senti Bio extends cash runway into Q4 2024 via GeneFab deal, Q2 net loss $18.7M

## Summary
- GeneFab transaction provides up to $38M in cash by end of 2025; extends cash runway into Q4 2024.
- IND for SENTI-202 (Logic Gated CAR-NK for AML) on track for 2H 2023; Phase 1 enrollment expected 2024.
- Cash, equivalents & short-term investments $59.6M as of June 30, 2023.
- Q2 net loss $18.7M ($0.42/share); R&D $11.0M (up from $9.2M), G&A $9.6M (down from $13.9M).
- Senti subleases Alameda cGMP facility to GeneFab; co-founder Philip Lee named GeneFab CEO.

## SEC filing metadata
- accession: 0001854270-23-000103
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000103/0001854270-23-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000103/snti-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-23-000103
- JSON: https://secwatch.observer/filing/0001854270-23-000103.json
- Plain text: https://secwatch.observer/filing/0001854270-23-000103.txt

## Key facts
- Earnings Releases
  Senti Biosciences, Inc. reported financial results for quarter ended June 30, 2023.
  - Period: quarter ended June 30, 2023
  - Result: reported results
  source text: On August 11, 2023, Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000103/0001854270-23-000103-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.